Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.71 |
| ▸ | RECQL | P46063 | 5/20 | 0.71 |
| ▸ | GAA | P10253 | 2/20 | 0.71 |
| ▸ | DBH | P09172 | 1/20 | 0.71 |
| ▸ | CA12 | O43570 | 4/20 | 0.55 |
| ▸ | CA1 | P00915 | 4/20 | 0.55 |
| ▸ | CA2 | P00918 | 4/20 | 0.55 |
| ▸ | CA7 | P43166 | 4/20 | 0.55 |
| ▸ | CA9 | Q16790 | 4/20 | 0.55 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.55 |
| ▸ | MAPT | P10636 | 4/20 | 0.52 |
| ▸ | POLB | P06746 | 2/20 | 0.52 |
| ▸ | CA4 | P22748 | 1/20 | 0.52 |
| ▸ | CA6 | P23280 | 1/20 | 0.52 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | XDH | P47989 | 1/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4953998 | 1.00 | KDM4E (0.71) | KDM4ERECQLGAADBHCA12 | |
| SCHEMBL10042363 | 0.85 | GAA (0.52) | KDM4ERECQLGAADBHCA12 | |
| SCHEMBL11536841 | 0.85 | KDM4E (0.67) | KDM4ERECQLGAADBHCA12 | |
| SCHEMBL8471397 | 0.83 | KDM4E (1.00) | KDM4ERECQLGAADBHCA12 | |
| SCHEMBL28987669 | 0.83 | HSP90AA1 (0.50) | KDM4ERECQLGAADBHCA12 | |
| Hydrochloric Acid SCHEMBL11290292 | 0.83 | KDM4E (0.65) | KDM4ERECQLGAADBHCA12 | |
| SCHEMBL2988488 | 0.82 | KDM4E (0.74) | KDM4ERECQLGAADBHCA12 | |
| SCHEMBL8982946 | 0.80 | KDM4E (0.71) | KDM4ERECQLGAADBHCA12 | |
| Hydrochloric Acid SCHEMBL11288312 | 0.78 | KDM4E (0.58) | KDM4ERECQLGAADBHCA12 | |
| SCHEMBL9407168 | 0.77 | KDM4E (0.67) | KDM4ERECQLGAADBHCA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9266817-B2 | Catecholamine derivatives for obesity and neurological disorders | EMORY UNIVERSITY (US) | 2016-02-23 | — | — | US | disclosed |
| US-9266817-B2 | Catecholamine derivatives for obesity and neurological disorders | EMORY UNIVERSITY (US) | 2016-02-23 | — | — | US | disclosed |
| US-9266817-B2 | Catecholamine derivatives for obesity and neurological disorders | EMORY UNIVERSITY (US) | 2016-02-23 | — | — | US | disclosed |
| US-20140329907-A1 | CATECHOLAMINE DERIVATIVES FOR OBESITY AND NEUROLOGICAL DISORDERS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2014-11-06 | — | — | US | disclosed |
| US-20140329907-A1 | CATECHOLAMINE DERIVATIVES FOR OBESITY AND NEUROLOGICAL DISORDERS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2014-11-06 | — | — | US | disclosed |
| US-20140329907-A1 | CATECHOLAMINE DERIVATIVES FOR OBESITY AND NEUROLOGICAL DISORDERS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2014-11-06 | — | — | US | disclosed |
| US-20120022086-A1 | CATECHOLAMINE DERIVATIVES FOR OBESITY AND NEUROLOGICAL DISORDERS | EMORY UNIVERSITY (US) | 2012-01-26 | — | — | US | disclosed |
| US-20120022086-A1 | CATECHOLAMINE DERIVATIVES FOR OBESITY AND NEUROLOGICAL DISORDERS | EMORY UNIVERSITY (US) | 2012-01-26 | — | — | US | disclosed |
| US-20120022086-A1 | CATECHOLAMINE DERIVATIVES FOR OBESITY AND NEUROLOGICAL DISORDERS | EMORY UNIVERSITY (US) | 2012-01-26 | — | — | US | disclosed |
| WO-2010107866-A2 | CATECHOLAMINE DERIVATIVES FOR OBESITY AND NEUROLOGICAL DISORDERS | EMORY UNIVERSITY (US) | 2010-09-23 | — | — | WO | disclosed |
| WO-2010107866-A2 | CATECHOLAMINE DERIVATIVES FOR OBESITY AND NEUROLOGICAL DISORDERS | EMORY UNIVERSITY (US) | 2010-09-23 | — | — | WO | disclosed |
| US-7462658-B2 | Aging-resistant coatings and adhesive composites | HENKEL AG & CO. KGAA (DE) | 2008-12-09 | — | — | US | disclosed |
| US-20070231582-A1 | AGING-RESISTANT COATINGS AND AHESIVE COMPOSITES | HENKEL AG & CO. KGAA (DE) | 2007-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022086-A1 | CATECHOLAMINE DERIVATIVES FOR OBESITY AND NEUROLOGICAL DISORDERS | BDNF, NTRK2, COMT | KDM4E 2077/4885RECQL 3631/4885GAA 294/4885 |
| US-20140329907-A1 | CATECHOLAMINE DERIVATIVES FOR OBESITY AND NEUROLOGICAL DISORDERS | BDNF, NTRK2, COMT | KDM4E 2077/4885RECQL 3631/4885GAA 294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.